AN2 Therapeutics (ANTX) EPS (Weighted Average and Diluted) (2021 - 2026)
AN2 Therapeutics (ANTX) reported EPS (Weighted Average and Diluted) of -$0.29 for Q1 2026, up 17.14% year-over-year from -$0.25 in Q1 2025, and down 3.57% quarter-over-quarter from -$0.28 in Q4 2025.
AN2 Therapeutics (ANTX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.29 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.29, up 17.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.09 (up 27.81% YoY), and the FY2025 annual result was -$1.16, up 32.56% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.29 in Q1 2026 per ANTX's latest filing, from -$0.28 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.21 in Q2 2025 and troughed at -$2.98 in Q1 2022.
- A 5-year average of -$0.62 and a median of -$0.52 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) soared 83.8% in 2022, then sank 52.83% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.58 in 2022, then increased by 10.34% to -$0.52 in 2023, then jumped by 51.92% to -$0.25 in 2024, then retreated by 12.0% to -$0.28 in 2025, then retreated by 3.57% to -$0.29 in 2026.
- Business Quant data shows ANTX's EPS (Weighted Average and Diluted) at -$0.29 in Q1 2026, -$0.28 in Q4 2025, and -$0.31 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.29 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.21 |
| Mar 31, 2025 | -0.35 |
| Dec 31, 2024 | -0.25 |
| Sep 30, 2024 | -0.43 |
| Jun 30, 2024 | -0.48 |
| Mar 31, 2024 | -0.56 |
| Dec 31, 2023 | -0.52 |
| Sep 30, 2023 | -0.65 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.79 |
| Dec 31, 2022 | -0.58 |
| Sep 30, 2022 | -0.59 |
| Jun 30, 2022 | -0.53 |
| Mar 31, 2022 | -2.98 |
| Dec 31, 2021 | -3.58 |
| Sep 30, 2021 | -3.35 |
| Jun 30, 2021 | -2.62 |